Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Down 2.4% – What’s Next?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) shares dropped 2.4% on Monday . The stock traded as low as $1.98 and last traded at $2.04. Approximately 46,553 shares changed hands during mid-day trading, an increase of 78% from the average daily volume of 26,190 shares. The stock had previously closed at $2.09.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a research report on Wednesday, January 28th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $10.00.

Kiora Pharmaceuticals Trading Down 1.0%

The firm has a market capitalization of $7.51 million, a price-to-earnings ratio of -0.98 and a beta of -0.80. The firm has a fifty day moving average price of $2.12 and a 200 day moving average price of $2.25.

Institutional Trading of Kiora Pharmaceuticals

Large investors have recently made changes to their positions in the business. Alyeska Investment Group L.P. acquired a new stake in shares of Kiora Pharmaceuticals in the fourth quarter valued at $152,000. DRW Securities LLC lifted its position in Kiora Pharmaceuticals by 199.2% during the 4th quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock worth $217,000 after buying an additional 73,417 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Kiora Pharmaceuticals by 71.0% during the 4th quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock worth $42,000 after acquiring an additional 8,800 shares during the last quarter. Citadel Advisors LLC bought a new stake in Kiora Pharmaceuticals during the 3rd quarter worth about $125,000. Finally, Two Sigma Investments LP bought a new position in shares of Kiora Pharmaceuticals in the third quarter worth about $33,000. Institutional investors own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.